Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Yaozong Yuan

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008456162. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2011: 3 papers · 2012: 6 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper

Papers 23

  1. Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition. Last author DOI 10.1016/j.omto.2021.01.013↗
  2. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.04.004↗
  3. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-020-01689-6↗
  4. Cigarette Smoking and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Last author DOI 10.1097/mpa.0000000000001383↗
  5. Silencing of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition Last author DOI 10.21203/rs.2.12426/v2↗
  6. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes. Last author DOI 10.18632/oncotarget.16249↗
  7. Effect of p53 on pancreatic cancer-glucose tolerance abnormalities by regulating transglutaminase 2 in resistance to glucose metabolic stress. Last author DOI 10.18632/oncotarget.19402↗
  8. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. Last author DOI 10.1111/1753-0407.12313↗
  9. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. First author DOI 10.1159/000447872↗
  10. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000271↗
  11. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Co-author DOI 10.1111/cas.12747↗
  12. High neuropilin 1 expression was associated with angiogenesis and poor overall survival in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000117↗
  13. Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Last author DOI 10.3892/etm.2014.1519↗
  14. Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Last author DOI 10.1111/cas.12107↗
  15. Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus. Co-author DOI 10.1002/dmrr.1284↗
  16. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. First author DOI 10.1016/j.diabres.2011.12.028↗
  17. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Last author DOI 10.1093/carcin/bgs002↗
  18. Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. Co-author DOI 10.1097/mpa.0b013e31822ca176↗
  19. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗
  20. Connexin 43 interacts with Bax to regulate apoptosis of pancreatic cancer through a gap junction-independent pathway. Co-author DOI 10.3892/ijo.2012.1524↗
  21. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Co-author DOI 10.1002/ijc.25426↗
  22. Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Last author DOI 10.1016/j.canlet.2011.03.011↗
  23. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Co-author DOI 10.1016/j.ejca.2010.07.010↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiwen Ben · 12 shared papers, 2011–2020 · strength 0.75
  2. Yunwei Sun · 4 shared papers, 2019–2021 · strength 0.53
  3. Xiangyi He · 5 shared papers, 2012–2021 · strength 0.44
  4. Duowu Zou · 3 shared papers, 2019–2020 · strength 0.37
  5. Weiyan Yao · 7 shared papers, 2011–2017 · strength 0.33
  6. Wei An · 3 shared papers, 2014–2020 · strength 0.22
  7. Lifu Wang · 2 shared papers, 2015–2019 · strength 0.17
  8. Cheng Wang · 3 shared papers, 2012–2016 · strength 0.14
  9. Kaixuan Wang · 4 shared papers, 2011–2012 · strength 0.13
  10. Yongping Zhang · 2 shared papers, 2012–2017 · strength 0.12
  11. Zhao‐Shen Li · 3 shared papers, 2011–2014 · strength 0.11
  12. Wenjing Pang · 2 shared papers, 2015–2016 · strength 0.11
  13. Xin Dai · 2 shared papers, 2015–2016 · strength 0.11
  14. Wei‐Guang Li · 2 shared papers, 2012–2017 · strength 0.10
  15. Jian Fei · 2 shared papers, 2014 · strength 0.09
  16. Zhaoshen Li · 3 shared papers, 2011–2012 · strength 0.09
  17. Rui Liu · 2 shared papers, 2012–2016 · strength 0.09
  18. Yi Ba · 2 shared papers, 2012–2016 · strength 0.09
  19. Yufen Zhou · 1 shared paper, 2017 · strength 0.08
  20. Lei Wang · 1 shared paper, 2017 · strength 0.08
  21. Xiao Hua Su · 1 shared paper, 2017 · strength 0.06
  22. Ping Chen · 1 shared paper, 2017 · strength 0.06
  23. Yi Zang · 1 shared paper, 2017 · strength 0.06
  24. Ting Deng · 1 shared paper, 2016 · strength 0.06
  25. Quan-cai Cai · 2 shared papers, 2011–2012 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.